Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Times Interest Earned (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Times Interest Earned over the past 12 years, most recently at -$37.4 for Q4 2025.

  • Quarterly results put Times Interest Earned at -$37.4 for Q4 2025, up 77.89% from a year ago — trailing twelve months through Dec 2025 was -$73.53 (up 45.17% YoY), and the annual figure for FY2025 was -$73.44, up 46.04%.
  • Times Interest Earned for Q4 2025 was -$37.4 at Viridian Therapeutics, Inc.\DE, up from -$71.45 in the prior quarter.
  • Over the last five years, Times Interest Earned for VRDN hit a ceiling of -$37.4 in Q4 2025 and a floor of -$9693.7 in Q4 2021.
  • Median Times Interest Earned over the past 5 years was -$173.94 (2023), compared with a mean of -$777.47.
  • Biggest five-year swings in Times Interest Earned: plummeted 1825.94% in 2021 and later surged 96.99% in 2022.
  • Viridian Therapeutics, Inc.\DE's Times Interest Earned stood at -$9693.7 in 2021, then surged by 96.99% to -$292.06 in 2022, then skyrocketed by 38.82% to -$178.7 in 2023, then grew by 5.32% to -$169.19 in 2024, then soared by 77.89% to -$37.4 in 2025.
  • The last three reported values for Times Interest Earned were -$37.4 (Q4 2025), -$71.45 (Q3 2025), and -$207.72 (Q2 2025) per Business Quant data.